NCT01530048
Completed
Phase 1
A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial, Assessing the Bioequivalence Between Insulin Aspart 100 U/mL and Insulin Aspart 200 U/mL in Healthy Individuals
Overview
- Phase
- Phase 1
- Intervention
- insulin aspart
- Conditions
- Diabetes
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Cmax, maximum concentration
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This trial is conducted in Europe. The aim of this trial is to test if there is bioequivalence between the insulin aspart 100 U/mL (U100) formulation and the new insulin aspart 200 U/mL (U200) formulation.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Considered to be healthy as judged from vital signs, medical history, ECG (electrocardiogram), laboratory values, and physical examination
- •Body mass index between 18 and 27 kg/m\^2 (both inclusive)
- •Non-smoker
- •Fasting blood glucose maximum 6 mmol/L
- •HbA1c below 6.4%
Exclusion Criteria
- •Pregnant or breast-feeding women
- •Women not using acceptable methods of contraception without difficulties for at least three months prior to trial start (screening), including intrauterine devices, oral contraceptives, hormonal implants, or sterilisation
- •Clinically significant abnormal laboratory values (as judged by the Investigator)
- •Close relative with type 1 diabetes mellitus (father, mother, sister or brother)
- •Intake of alcohol within the last 24 hours prior to screening and drug administration visits
- •Blood donation or blood loss of more than 500 mL within the 3 last months before screening
- •Strenuous exercise within 48 hours before screening as well as drug administration and followup
- •Smoking during the past month before drug administration
Arms & Interventions
U200
Intervention: insulin aspart
U100
Intervention: insulin aspart
Outcomes
Primary Outcomes
Cmax, maximum concentration
Area under the curve (AUC) in the interval of 0-6 hours
Secondary Outcomes
- Vz/f, volume of distribution during terminal phase
- GIRmax, maximum glucose infusion rate value
- tGIRmax, time to maximum glucose infusion rate value
- AUC in the interval of 0-infinity hours
- tmax, time to reach Cmax
- Terminal rate constant
- t½, terminal half-life
- AUCGIR, area under the glucose infusion rate value curve
- Adverse events
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioequivalence of Two Mixtard® 30 Formulations in Healthy SubjectsDiabetesHealthyNCT01486888Novo Nordisk A/S45
Completed
Phase 1
Bioequivalence of Two Insulatard® Formulations in Healthy SubjectsDiabetesHealthyNCT01486901Novo Nordisk A/S44
Completed
Phase 1
Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy SubjectsDiabetesHealthyNCT01868581Novo Nordisk A/S58
Completed
Phase 1
Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy SubjectsDiabetesHealthyNCT01490099Novo Nordisk A/S37
Completed
Phase 1
A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing ProcessesDiabetesHealthyNCT01766245Novo Nordisk A/S28